Recap: UroGen Pharma Q3 Earnings

Shares of UroGen Pharma URGN were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share were down 23.58% over the past year to ($1.31), which beat the estimate of ($1.49).

Revenue of $3,461,000 up by 0.00% year over year, which beat the estimate of $3,340,000.

Guidance

UroGen Pharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/gh8p8meu

Recent Stock Performance

Company's 52-week high was at $35.21

52-week low: $13.12

Price action over last quarter: down 1.98%

Company Profile

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. It has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The company's lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.